New Data from Phase 3 Studies Provide Additional Evidence Supporting Treatment Effect for Oral BG-12 (Dimethyl Fumarate) in Multiple Sclerosis WESTON, Mass.--(BUSINESS WIRE)--Oct. 12, 2012-- Today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results